British Columbia becomes final jurisdiction to fund the life changing cystic fibrosis drug
Read MoreNews
All media inquiries can be directed to mediarelations@cysticfibrosis.ca or by calling 1-800-378-2233.
Cystic Fibrosis Canada urges British Columbia, the last jurisdiction to fund the drug for children, to fund Trikafta using CADTH’s new guidance
Read MoreCystic Fibrosis Canada calls on remaining provinces to fund Trikafta for children six and up and lift any overly-restrictive access criterion
Read MoreCystic Fibrosis Canada calls on remaining provinces and territories to fund Trikafta for children six and up and lift any overly-restrictive access criterion.
Read MoreCystic Fibrosis Canada calls on remaining provinces and territories to fund Trikafta for children six and up and lift any overly-restrictive access criteria.
Read MoreCystic Fibrosis Canada calls on remaining provinces and territories to fund Trikafta for children six and up and lift any overly-restrictive access criteria.
Read MoreCystic Fibrosis Canada calls on remaining provinces and territories to fund Trikafta for children six and up and lift any overly-restrictive access criteria
Read MoreCystic Fibrosis Canada is calling on Quebec Health Minister to fund Trikafta now.
Read MoreTORONTO, August 3, 2022 – The Northwest Territories and Non-Insured Health Benefits (NIHB) have completed an agreement with the manufacturer of Trikafta to fund the revolutionary cystic fibrosis (CF) drug for people aged six years and older, effective July 29, 2022.
Read More